Clinical trials: Torsades de Pointes
Torsades de Pointe Caused by Drug
A Pharmacovigilance Study of Torsade de Pointes
Many cardiac and non-cardiac drugs are associated with TdP that may constitute a significant problem because of sudden cardiac death.
- Trial name
- NCT04293432
- Testing
- Drugs, Generic
- Where
- Pakistan
- Volunteers
- 6,670 people
- Sponsor
- University of Peshawar
Premature Ovarian Insufficiency
Ventricular Repolarization in Patients With Premature Ovarian Insufficiency (QTIOP)
Ventricular repolarization, measured by corrected QT interval (QTc), is influenced by sex hormones. A QTc above 460msec predisposes to the risk of "torsades-de-pointes"(TdP).
- Trial name
- QTIOP (NCT04167033)
- Testing
- Hormone replacement therapy:effect on ventricular repolarization, ECG
- Where
- 3 sites in France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Torsades de Pointe Caused by Drug (Disorder), Torsades de Pointes
Pharmacist Use of ECG to Inform Drug Therapy Decisions for Patients Receiving QT Prolonging Medications
Torsade de pointes (TdP) is a cardiac arrhythmia associated with QT interval prolongation which may lead to cardiac arrest. Prescription medications which cause QT interval prolongation are commonly used in daily practice.
- Conditions
- Torsades de Pointe Caused by Drug (Disorder), Torsades de Pointes, Qt Interval, Variation in
- Trial name
- NCT04000542
- Testing
- Pharmacist Intervention
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Northeast Iowa Medical Education Foundation
Long qt Syndrome, Torsade de Pointes
A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes
This is a registry to examine genetic and clinical predictors of torsade de pointes events.
- Trial name
- BA-TdP (NCT02439645)
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- Massachusetts General Hospital
QT-prolongation
QT-prolongation in Psychiatric Hospitals
Observational study in 6 psychiatric hospitals in Flanders. Patients are included when a QT-prolonging drug is added to a medication profile that already contains a potential QT-prolonging drug.
- Trial name
- NCT02043925
- Testing
- drugs linked with QT-prolongation
- Where
- Belgium
- Volunteers
- 152 people
- Sponsor
- KU Leuven
Arrhythmia, SARS-CoV-2 Infection
Study of Arrhythmia and ECG Abnormalities in Patients With COVID-19
Cardiac involvement has been described in Severe Acute Respiratory Syndrome - Coronavirus-2 (SARS-CoV-2) infection. Although there are no approved drugs to prevent or treat SARS-CoV-2 infection at present time, several…
- Trial name
- RYTHMO-COV (NCT04937621)
- Testing
- ECG data analysis, Treatment data collect, Biological check-up data collect
- Where
- France
- Volunteers
- 196 people
- Sponsor
- University Hospital, Bordeaux
QT-prolongation
Drug Interactions With Risk of QT-prolongation in a General Hospital
In this epidemiological point prevalence study, medication profiles of patients with haloperidol treatment will be checked for drug interactions with risk of QT-prolongation.
- Trial name
- NCT02043912
- Testing
- Haloperidol
- Where
- Belgium
- Volunteers
- 222 people
- Sponsor
- KU Leuven
Torsades de Pointes
A Study to Evaluate How VI-0521 Affect Cardiac Repolarization in Healthy Male and Female Volunteers
Determine whether VI-0521 has an effect on the electrical activity of the heart in healthy subjects. Find out how much VI-0521 is in the blood and any potential side effects on ECG's of healthy subjects after taking the study…
- Trial name
- TQT (NCT00839891)
- Testing
- VI-0521
- Where
- United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Arrhythmias, Cardiac, Atrial Fibrillation
Clinical Cohort Study - TRUST
The "Long-term Outcome and Predictors for Recurrence after Medical and Interventional Treatment of Arrhythmias at the University Heart Center Hamburg" (TRUST) study is an investor-initiated, single-center, prospective clinical…
- Conditions
- Arrhythmias, Cardiac, Atrial Fibrillation, Atrial Flutter, Ventricular Tachycardia
- Trial name
- TRUST (NCT05521451)
- Where
- Germany
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf
Long QT Syndrome
Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
Torsades de pointes (TdP) is a potentially fatal ventricular arrhythmia associated with corrected QT (QTc) interval prolongation.
- Trial name
- NCT02513940
- Testing
- Testosterone, Progesterone, Ibutilide
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Indiana University
Acquired Long QT, Ventricular Arrhythmias
Do QT-Prolonging Drugs Cause Major Adverse Cardiac Events in Hospitalized Adults?
There are 28 non-cardiology medications from multiple families costing more than $13 billion annually in Canada, categorized as 'Known' QT-prolonging medications (QTPmeds) based on very low levels of evidence.
- Conditions
- Acquired Long QT, Ventricular Arrhythmias, Torsades de Pointes, Syncope
- Trial name
- QTP-MACE (NCT07374263)
- Where
- 2 sites in Canada
- Volunteers
- 990,000 people
- Sponsor
- St. Joseph's Healthcare Hamilton
Prolonged QT Interval in EKG and Sudden Death
Influence of Progesterone Administration on Drug-Induced QT Interval Lengthening
Female sex is an independent risk factor for the potentially fatal drug-induced arrhythmia (irregular heartbeat) known as torsades de pointes (TdP), which is associated with prolongation of the corrected QT (QTc) interval on the…
- Trial name
- NCT01929083
- Testing
- Progesterone, Ibutilide
- Where
- 2 sites in United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Indiana University
Delirium, QT-prolongation
Risk of QT-prolongation and Torsade de Pointes in Patients Treated With Acute Medication in a University Hospital
A prospective, observational study in a university hospital (UZ Leuven). Patients are included when they are treated with a potentional QT-prolonging drug: haloperidol for delirium, antibiotics (moxifloxacin, levofloxacin…
- Trial name
- RISQ-PATH (NCT02068170)
- Testing
- Haloperidol, azi/clari/erythromycin, levo/moxifloxacin, co-trimoxazole, vori/keto/flu/itraconazole, methadone, tacrolimus, sunitinib
- Where
- Belgium
- Volunteers
- 178 people
- Sponsor
- KU Leuven
Carcinoma, Renal Cell
Cardiovascular and Torsades de Pointes Monitoring for Pazopanib
This observational study is conducted as part of a systematic pharmacovigilance activity, to provide a population-based context for Pazopanib use outside of the clinical trial setting.
- Trial name
- NCT01446224
- Testing
- Pazopanib, Other anti-VEGFs
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
COVID-19
Safety of Short-term Hydroxychloroquine Plus Azithromycin Treatment in Critically Ill Patients With Severe COVID-19
Hydroxychloroquine and azithromycin have been proposed as treatment of COVID-19 patients, but few reports have assessed this combination therapy in critically ill COVID-19 patients.
- Trial name
- NCT04452617
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Institut Mutualiste Montsouris
Diabetes Type 2, Hyperglycaemia (Diabetic)
Effect of Hyperglycaemia and Moxifloxacin on QTc Interval in T2DM
Diabetes is a significant risk factor for sudden cardiac death, with the QTc interval on electrocardiograms (ECGs) often prolonged in diabetic patients due to factors such as hyperglycaemia and insulin resistance.
- Conditions
- Diabetes Type 2, Hyperglycaemia (Diabetic), QT Interval, Variation in, Torsades de Pointes
- Trial name
- NCT07014735
- Testing
- glucose, moxifloxacin
- Where
- United Kingdom
- Volunteers
- 14 people
- Sponsor
- Richmond Pharmacology Limited